Results 161 to 170 of about 19,315 (197)
Adenosine and Ticagrelor Plasma Levels in Patients With and Without Ticagrelor-Related Dyspnea [PDF]
Circulation, 2018 Dyspnea is a common side effect of ticagrelor, leading to drug discontinuation in roughly one in every 20 treated patients. Studies have suggested that ticagrelor inhibits the sodium-independent equilibrative nucleoside transporter-1, which may increase ...
Luis Ortega-Paz +2 more
exaly +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
2022
Ticagrelor is one of the most recent antiplatelet agents used to inhibit platelet aggregation via blocking the ADP receptors of the subtype P2Y12. It belongs to the non-thienopyridine class. The drug was first discovered by Astra Zeneca and approved for use in 2011 by the FDA.
Mohamed Fawzy, Kabil +2 more
openaire +2 more sources
Ticagrelor is one of the most recent antiplatelet agents used to inhibit platelet aggregation via blocking the ADP receptors of the subtype P2Y12. It belongs to the non-thienopyridine class. The drug was first discovered by Astra Zeneca and approved for use in 2011 by the FDA.
Mohamed Fawzy, Kabil +2 more
openaire +2 more sources
Drugs of Today, 2010
Coronary artery disease (CAD) is the single leading cause of death in the U.S. Therapies for CAD have been developed to inhibit platelet aggregation underlying atherogenesis. Clinical benefit has been shown with antagonists of the P2Y(12) receptor, such as clopidogrel. However, concerns over patient resistance to treatment and relatively slow onset and
openaire +2 more sources
Coronary artery disease (CAD) is the single leading cause of death in the U.S. Therapies for CAD have been developed to inhibit platelet aggregation underlying atherogenesis. Clinical benefit has been shown with antagonists of the P2Y(12) receptor, such as clopidogrel. However, concerns over patient resistance to treatment and relatively slow onset and
openaire +2 more sources